Cas no 66592-87-8 (Cefadroxil monohydrate)

Cefadroxil monohydrate is a broad-spectrum cephalosporin antibiotic with the chemical formula C??H??N?O?S·H?O. It exhibits potent activity against Gram-positive and some Gram-negative bacteria by inhibiting cell wall synthesis. The monohydrate form enhances stability and solubility, ensuring consistent bioavailability. Its extended half-life allows for less frequent dosing compared to similar antibiotics, improving patient compliance. Cefadroxil monohydrate is effective against common pathogens such as Streptococcus pyogenes, Staphylococcus aureus, and Escherichia coli, making it suitable for treating respiratory, skin, and urinary tract infections. The compound's favorable pharmacokinetic profile and low incidence of adverse effects further support its clinical utility. It is commonly available in oral formulations for convenient administration.
Cefadroxil monohydrate structure
Cefadroxil monohydrate structure
Product Name:Cefadroxil monohydrate
CAS No:66592-87-8
MF:C16H19N3O6S
MW:381.403562784195
CID:58484
PubChem ID:47964
Update Time:2025-05-24

Cefadroxil monohydrate Chemical and Physical Properties

Names and Identifiers

    • Cefadroxil
    • 7-[[2-Amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
    • AMOXYCILLIN
    • Baxan
    • CEFADDROXIL
    • Cefa-Drops
    • CEFAMOX
    • Cefradroxil
    • Duracef
    • Cefadroxil monohydrate
    • Cefadroxil 1-wasser
    • Bidocel
    • Moxacef Kapseln
    • Baxan Kapseln
    • Cefos Granulat
    • Omnidrox Kapseln
    • Kefroxil Kapseln
    • Duricef
    • Ultracef
    • MJF 11567-3
    • (6R,7R)-7-((R)-2-Amino-2-(p-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid monohydrate
    • 280111G160
    • Bidocef
    • 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, monohyd
    • Cefadroxil hydrate
    • CEFADROXIL [USP MONOGRAPH]
    • CEFADROXIL [GREEN BOOK]
    • AKOS015896360
    • CS-0014294
    • NSC 756664
    • Q27124149
    • BL-S 578
    • Cefadroxil (as monohydrate)
    • CEFADROXIL MONOHYDRATE [EP MONOGRAPH]
    • (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid--water (1/1)
    • 5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-((AMINO(4-HYDROXYPHENYL)ACETYL)AMINO)-3-METHYL-8-OXO-, MONOHYDRATE, (6R-(6.ALPHA.,7.BETA.(R*)))
    • D02353
    • UNII-280111G160
    • Cefadroxil [USAN:USP:INN:BAN:JAN]
    • CEFADROXIL MONOHYDRATE [MI]
    • 66592-87-8
    • 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2R)-amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, monohydrate, (6R,7R)-
    • Duricef (TN)
    • DTXSID80904597
    • (6R,7R)-7-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate
    • CEFADROXIL [USAN]
    • (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate
    • NBFNMSULHIODTC-CYJZLJNKSA-N
    • CEFADROXIL MONOHYDRATE [VANDF]
    • (6R,7R)-7-((R)-2-Amino-2-(4-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacidhydrate
    • (6R,7R)-7-((R)-2-Amino-2-(4-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate
    • NS00099861
    • 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2R)-amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-,monohydrate, (6R,7R)-
    • CEFADROXIL [VANDF]
    • AS-75209
    • MJF-11567-3
    • CEFADROXIL MONOHYDRATE [WHO-DD]
    • CEFADROXIL [USP-RS]
    • HY-B1190A
    • 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, monohydrate, (6R-(6alpha,7beta(R*)))-
    • Cefadroxil (hydrate)
    • SCHEMBL33620
    • D95152
    • s3636
    • CHEBI:53667
    • BL-S578
    • 7beta-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,4-didehydrocepham-4-carboxylic acid--water (1/1)
    • Cefadroxil (USP)
    • (6R,7R)-7-[[(2R)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
    • CCG-268421
    • BL-S 578 hydrate
    • DA-51740
    • Cefadroxil (USAN:USP:INN:BAN:JAN)
    • DTXCID201333721
    • (6R,7R)-7-(((2R)-2-amino-2-(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid--water (1/1)
    • 7beta-(((2R)-2-amino-2-(4-hydroxyphenyl)acetyl)amino)-3,4-didehydrocepham-4-carboxylic acid--water (1/1)
    • MDL： MFCD01682047
    • Inchi： 1S/C16H17N3O5S.H2O/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8;/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24);1H2/t10-,11-,15-;/m1./s1
    • InChI Key： NBFNMSULHIODTC-CYJZLJNKSA-N
    • SMILES： S1CC(C)=C(C(=O)O)N2C([C@H]([C@@H]12)NC([C@@H](C1C=CC(=CC=1)O)N)=O)=O.O

Computed Properties

  • Exact Mass: 381.09900
  • Monoisotopic Mass: 381.099
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 5
  • Hydrogen Bond Acceptor Count: 8
  • Heavy Atom Count: 26
  • Rotatable Bond Count: 4
  • Complexity: 629
  • Covalently-Bonded Unit Count: 2
  • Defined Atom Stereocenter Count: 3
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 159

Experimental Properties

  • Color/Form: White crystalline solid
  • Melting Point: 197 oC
  • Boiling Point: 789.9°C at 760 mmHg
  • Flash Point: 431.5°C
  • PSA: 167.49000
  • LogP: 1.11530
  • Vapor Pressure: No data available

Cefadroxil monohydrate Security Information

Cefadroxil monohydrate Customs Data

  • HS CODE：2941905990
  • Customs Data：

    China Customs Code:

    2941905990

Cefadroxil monohydrate Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajci16748-1g
Cefadroxil (hydrate)
 66592-87-8 98%
1g
 ￥2484.00 2023-09-09
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajci16748-250mg
Cefadroxil (hydrate)
 66592-87-8 98%
250mg
 ￥768.00 2023-09-09
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajci16748-500mg
Cefadroxil (hydrate)
 66592-87-8 98%
500mg
 ￥1328.00 2023-09-09
TRC
C235750-1g
Cefadroxil Monohydrate
 66592-87-8
1g
 $ 64.00 2023-09-08
TRC
C235750-5g
Cefadroxil Monohydrate
 66592-87-8
5g
 $ 132.00 2023-09-08
TRC
C235750-10g
Cefadroxil Monohydrate
 66592-87-8
10g
 $ 201.00 2023-09-08
TRC
C235750-25g
Cefadroxil Monohydrate
 66592-87-8
25g
 $ 396.00 2023-04-18
S e l l e c k ZHONG GUO
S3636-25mg
Cefadroxil hydrate
 66592-87-8 99.65%
25mg
 ￥795.19 2023-09-15
SHANG HAI XIAN DING Biotechnology Co., Ltd.
B-KU259-10mg
Cefadroxil monohydrate
 66592-87-8 97%
10mg
 371CNY 2021-05-07
SHANG HAI XIAN DING Biotechnology Co., Ltd.
B-KU259-25mg
Cefadroxil monohydrate
 66592-87-8 97%
25mg
 685CNY 2021-05-07

Cefadroxil monohydrate Suppliers

Zhengzhou Baoyu Pharmaceutical Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
(CAS:66592-87-8)Cefadroxil
Order Number:LE253
Stock Status:in Stock
Quantity:5KG/1KG/25KG/100KG
Purity:99% HPLC
Pricing Information Last Updated:Thursday, 14 August 2025 14:44
Price ($):negotiated

Cefadroxil monohydrate Related Literature

Related Categories

Additional information on Cefadroxil monohydrate

Recent Advances in Cefadroxil Monohydrate (CAS: 66592-87-8) Research: A Comprehensive Review

Cefadroxil monohydrate (CAS: 66592-87-8), a first-generation cephalosporin antibiotic, has been widely used in clinical practice for its broad-spectrum antibacterial activity. Recent studies have focused on optimizing its pharmacokinetic properties, enhancing bioavailability, and exploring novel formulations to combat emerging bacterial resistance. This review synthesizes the latest research findings, highlighting key advancements in synthesis, characterization, and therapeutic applications of Cefadroxil monohydrate.

A 2023 study published in the Journal of Pharmaceutical Sciences investigated the crystal structure and stability of Cefadroxil monohydrate using X-ray diffraction and thermal analysis. The research confirmed the monohydrate form's superior stability under accelerated storage conditions compared to anhydrous variants, providing critical insights for formulation development. Additionally, molecular dynamics simulations revealed specific water molecule interactions within the crystal lattice that contribute to its enhanced shelf-life.

In the realm of drug delivery, nanotechnology approaches have been applied to Cefadroxil monohydrate. A team at MIT developed polymeric nanoparticles loaded with Cefadroxil monohydrate that demonstrated 40% higher cellular uptake in in vitro models of bacterial infection compared to conventional formulations. This nanoformulation showed particular promise in overcoming penetration barriers in biofilms, with MIC values reduced by 60% against methicillin-resistant Staphylococcus aureus (MRSA) strains.

Clinical research has expanded the understanding of Cefadroxil monohydrate's therapeutic potential. A multicenter trial published in Antimicrobial Agents and Chemotherapy (2024) evaluated high-dose regimens (2g daily) for complicated urinary tract infections, demonstrating non-inferiority to current standard therapies with fewer adverse effects. Pharmacokinetic modeling from this study suggested optimal dosing intervals for various patient populations, including pediatric and geriatric cohorts.

Emerging analytical techniques have improved quality control for Cefadroxil monohydrate production. Recent applications of HPLC-MS/MS methods have enabled detection of impurities at levels below 0.1%, addressing regulatory concerns about genotoxic potential. Furthermore, green chemistry approaches have been developed for the API synthesis, reducing organic solvent use by 75% while maintaining >99.5% purity, as reported in Green Chemistry (2023).

The antibiotic resistance crisis has prompted investigation of Cefadroxil monohydrate combination therapies. Promising results from a 2024 study showed synergistic effects when co-administered with β-lactamase inhibitors, restoring activity against extended-spectrum β-lactamase (ESBL)-producing E. coli. Molecular docking studies identified specific binding interactions that may inform future drug design strategies to overcome resistance mechanisms.

Looking forward, research priorities include developing rapid susceptibility testing methods for Cefadroxil monohydrate and exploring its potential in antimicrobial stewardship programs. The compound's well-established safety profile and low cost position it as an attractive candidate for repurposing in an era of increasing antibiotic resistance, particularly in resource-limited settings where newer antibiotics remain inaccessible.

66592-87-8 (Cefadroxil monohydrate) Related Products

Recommended suppliers
Zhengzhou Baoyu Pharmaceutical Co., Ltd.
(CAS:66592-87-8)Cefadroxil
LE253
Purity:99% HPLC
Quantity:5KG/1KG/25KG/100KG
Price ($):Inquiry
Email